An Exploratory Phase II, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Pertuzumab and Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2016
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 20 Jul 2016 Study design changed from single group assignment to parallel group assignment and treatment arms changed from 1 to 2.
- 01 Apr 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 07 Oct 2013 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.